Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.71 (1.26%)
Data as of 09/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
08/19/15Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 19, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of James B. Jones, MD, PharmD, to the position of senior vice president and chief medical officer. Dr. Jones brings more than 25 years of experience as both a practicing and teaching physician and as a senior executive at biotechnology and pharmaceutical companies, where he led the clinical development of multiple novel pa... 
Printer Friendly Version
08/03/15Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 3, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the following investor conferences in August: Wedbush 2015 Life Sciences Management Access Conference at 8:00 a.m. ET in New York on Tuesday, August 11, 2015. ... 
Printer Friendly Version
07/30/15Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 30, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2015. “We recorded $57 million in EXPAREL product revenues in the second quarter, an increase o... 
Printer Friendly Version
07/15/15Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 15, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc. (NASDAQ: PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs. The randomized, blinded, multicenter pivotal study in dogs undergoing knee surger... 
Printer Friendly Version

Corporate Presentation

Corporate Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574